Jaume Mora

Dr. Jaume Mora

Hospital Sant Joan de Déu Barcelona, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2013 in Nature
Verified
Journal Article
Open access
PDF file
MLMichael S. Lawrence
Michael S. Lawrence
PSPetar Stojanov
Petar Stojanov
PPPaz Polak
Paz Polak
GKGregory V. Kryukov
Gregory V. Kryukov
KCKristian Cibulskis
Kristian Cibulskis
GGGad Getz
Gad Getz
As the sample size in cancer genome studies increases, the list of genes identified as significantly mutated is likely to include more false positives; here, this problem is identified as stemming largely from mutation heterogeneity, and a new analytical methodology designed to overcome this problem is described. Cancer genomic approaches have identified scores of genes responsible for the initiation and progression of cancer. But as the sample sizes increase, the list of putatively significant genes identified by current analytical methods continues to grow and is likely to include many false positives. This study shows that this situation stems largely from mutational heterogeneity and presents a novel methodology, MutSigCV, that overcomes the problem by incorporating mutational heterogeneity into the analysis. Application of MutSigCV to more than 3,000 tumour samples from 27 different tumour types shows that mutation frequencies vary more than 1,000-fold between extreme samples both between and within tumour types. And when applied to a data set on lung cancer, MutSigCV reduced the list of significantly mutated genes from 450 to a more manageable 11, most of them previously reported to be mutated in squamous cell lung cancer. Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer1,2,3,4,5,6,7,8,9. These studies involve the sequencing of matched tumour–normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour–normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.

1 June 2017 in Cancer Cell
Verified
Journal Article
Closed access
FCFlorence M.G. Cavalli
Florence M.G. Cavalli
MRMarc Remke
Marc Remke
LRLadislav Rampasek
Ladislav Rampasek
JPJohn Peacock
John Peacock
DSDavid J.H. Shih
David J.H. Shih
MTMichael D. Taylor
Michael D. Taylor

1 October 2017 in Cancer Cell
Verified
Journal Article
Open access
AMAlan Mackay
Alan Mackay
ABAnna Burford
Anna Burford
DCDiana Carvalho
Diana Carvalho
EIElisa Izquierdo
Elisa Izquierdo
JFJanat Fazal-Salom
Janat Fazal-Salom
CJChris Jones
Chris Jones
We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors. Genomic aberrations increase with age, highlighting the infant population as biologically and clinically distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the molecular diversity of the disease, opening up avenues for biological study and providing a basis for functionally defined future treatment stratification.

20 July 2017 in Nature
Verified
Journal Article
Open access
PDF file
PNPaul A. Northcott
Paul A. Northcott
IBIvo Buchhalter
Ivo Buchhalter
AMA. Sorana Morrissy
A. Sorana Morrissy
VHVolker Hovestadt
Volker Hovestadt
JWJoachim Weischenfeldt
Joachim Weischenfeldt
PLPeter Lichter
Peter Lichter
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.

11 January 2001 in Nature
Verified
Journal Article
Closed access
PDF file
MSMaría S. Soengas
María S. Soengas
PCPaola Capodieci
Paola Capodieci
DPDavid Polsky
David Polsky
Jaume MoraJaume Mora
Jaume Mora
MEManel Esteller
Manel Esteller
SLScott W. Lowe
Scott W. Lowe

28 February 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JSJack F. Shern
Jack F. Shern
LCL. Chen
L. Chen
TBThomas Badgett
Thomas Badgett
GGGad Getz
Gad Getz
JCJuliann Chmielecki
Juliann Chmielecki
DCDaniel Catchpoole
Daniel Catchpoole
Despite gains in survival, outcomes for patients with metastatic or recurrent rhabdomyosarcoma remain dismal. In a collaboration between the National Cancer Institute, Children's Oncology Group, and Broad Institute, we performed whole-genome, whole-exome, and transcriptome sequencing to characterize the landscape of somatic alterations in 147 tumor/normal pairs. Two genotypes are evident in rhabdomyosarcoma tumors: those characterized by the PAX3 or PAX7 fusion and those that lack these fusions but harbor mutations in key signaling pathways. The overall burden of somatic mutations in rhabdomyosarcoma is relatively low, especially in tumors that harbor a PAX3/7 gene fusion. In addition to previously reported mutations in NRAS, KRAS, HRAS, FGFR4, PIK3CA, and CTNNB1, we found novel recurrent mutations in FBXW7 and BCOR, providing potential new avenues for therapeutic intervention. Furthermore, alteration of the receptor tyrosine kinase/RAS/PIK3CA axis affects 93% of cases, providing a framework for genomics-directed therapies that might improve outcomes for patients with rhabdomyosarcoma. Significance: This is the most comprehensive genomic analysis of rhabdomyosarcoma to date. Despite a relatively low mutation rate, multiple genes were recurrently altered, including NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, and BCOR. In addition, a majority of rhabdomyosarcoma tumors alter the receptor tyrosine kinase/RAS/PIK3CA axis, providing an opportunity for genomics-guided intervention. Cancer Discov; 4(2); 216–31. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 131